The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million in common stock on the Nasdaq.
The company said the funding round raised nearly $140 million overall.
In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.
After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.
Canada begins its search for a chief government science advisor, Nature News reports.
A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.